BackMARX Biotech , Ltd. Overview

MARX Biotech , Ltd. Long Term Debt

Latest long-term debt for 7731.TWO: $150M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$149.40M
↓ 14.88% YoYΔ $-26.11M vs prior year quarter

Peer trimmed avg / median

Loading

MARX Biotech , Ltd. Long Term Debt History

Loading

MARX Biotech , Ltd. vs. peers: Long Term Debt Comparison

Loading

MARX Biotech , Ltd. Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

MARX Biotech , Ltd. (7731.TWO) FAQ

As of the most recent data (June 2026), 7731.TWO shows a long-term debt of $150M. That compares with $180M in the prior-year period — down 14.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 7731.TWO's long-term debt is now $150M (was $180M) — a 14.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether MARX Biotech , Ltd. is outperforming or lagging.

Tracking 7731.TWO's long-term debt over time shows whether MARX Biotech , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $150M That compares with $180M in the prior-year period — down 14.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has MARX Biotech , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $150M) with ownership activity and broader fundamentals.

MARX Biotech , Ltd.'s long-term debt is $150M; compare it with other Consumer Discretionary names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.